PharmaNutra company profile
Company profile
PharmaNutra has 128 employees and is headquartered in Pisa, Italy.
Food, pharmaceutical and dietary supplement manufacturers are the main buyers of this group, which sells its products and services in Europe, the Middle East, the Far East, North America, South America and other markets worldwide. Its operations cover food supplements, medical devices and the supply of raw materials and active ingredients. Among its brands, Sucrosomial is a delivery system built to improve nutrient uptake while reducing gastrointestinal discomfort, and Cetylated Fatty Acids is aimed at muscle and joint recovery in physiotherapy and sports. Body bioimpedance analysis instruments and software are sold through agents, distributors and online channels.
In the fiscal year ended December 2025, revenue reached 132.2 million euros, up 13.8% on the previous year, while net profit amounted to 20.0 million euros. The company employs 128 people and has its headquarters in Pisa, Italy, where it was founded in 2000.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Italy
- Headquarters
- Via Campodavela 1, 56122, Pisa
- Employees
- 128
- Chief executive
- Roberto Lacorte
- Founded
- 2000
- Fiscal year
- January - December
- Listing
- PHN · Borsa Italiana
- Currency
- EUR
- ISIN
- IT0005274094
- Website
- pharmanutra.it
PharmaNutra and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| PharmaNutraPHN | Italy | $875.44M | 128 | 21.7% | 35.0 |
| EvotecEVT | Germany | $579.17M | 4,379 | -18.0% | — |
| Faes FarmaFAE | Spain | $1.73B | 2,677 | 13.0% | 18.7 |
| FagronFAGR | Belgium | $1.9B | 4,880 | 14.3% | 18.8 |
| AlmirallALM | Spain | $2.53B | 2,108 | 9.6% | 32.1 |
| Siegfried HoldingSFZN | Switzerland | $3.53B | 4,454 | 16.7% | 17.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
